Astrocyte Announces Initiation of First-In-Human Phase 1 Study of the Promising Stroke and Traumatic Brain Injury Therapeutic, AST-004

15Jun

Groton, CT, June 15, 2022 – Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries, announced that the...

Posted by korinek
in Press Releases

Astrocyte Pharmaceuticals Announces Appointment of Christine Gallagher to Board of Directors

14Dec

Groton, CT, December 14, 2021 – Astrocyte Pharmaceuticals Inc., a drug discovery and development company developing novel cerebroprotective therapeutics for patients with brain injuries, announced today...

Posted by korinek
in Press Releases

Astrocyte Pharmaceuticals Announces Publication in the Journal Stroke of Results Supporting Advancement of AST-004 into in the Clinic

22Nov

Groton, CT, November 22, 2021 – Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for the treatment of brain injuries, today announced...

Posted by korinek
in Press Releases

MTEC Awards $3M to Astrocyte Pharmaceuticals for Clinical Study of AST-004

16Sep

Groton, CT, September 16, 2021 – Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for the treatment of neurodegenerative brain injuries,...

Posted by korinek
in Press Releases

Astrocyte Pharmaceuticals Awarded Major Grant to Further Develop Promising Treatment for Brain Injury

8Sep

Groton, CT, September 8, 2021 – Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for the treatment of brain injuries, announced...

Posted by korinek
in Press Releases

Lisa Manna Joins Astrocyte Pharmaceuticals as Vice President of Clinical Development Operations

1Jul

Lisa Manna, RN, MBA Groton, CT, July 1, 2021 – Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for the treatment of neurodegenerative...

Posted by korinek
in Press Releases

Astrocyte Pharmaceuticals Raises $6M Series A to Advance Next Generation Stroke and TBI Treatment to the Clinic

3May

Groton, CT, May 3, 2021 – Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for the treatment of neurodegenerative brain injuries,...

Posted by korinek
in Press Releases

Astrocyte Pharmaceuticals Announces Expanded Clinical Advisory Board

1Dec

Groton, CT, December 1, 2020 – Astrocyte Pharmaceuticals Inc., a privately held pharmaceutical company advancing neuroprotective treatments, announced the establishment of its Clinical Advisory Board...

Posted by korinek
in Press Releases

Astrocyte Pharmaceuticals Presents NHP Stroke Study at International Stroke Conference

21Feb

Cambridge, MA, February 21, 2020 – Astrocyte Pharmaceuticals Inc. presented the results of a key preclinical efficacy study today at the International Stroke Conference in Los Angeles demonstrating...

Posted by korinek
in Press Releases

Jeffrey L. Saver to Chair Astrocyte Pharmaceuticals’ Clinical Advisory Board

11Dec

Cambridge, MA, December 11, 2018 – Astrocyte Pharmaceuticals Inc., a privately held pharmaceutical company, today announced that Jeffrey L. Saver, M.D., has joined the company’s Scientific Advisory...

Posted by korinek
in Press Releases

Category: Press Releases